Corporate Symposia Schedule

Please join our discussion on recent developments in primary hemophagocytic lymphohistiocytosis (HLH), including;

• Awareness and diagnosis of primary HLH
• The role of IFNγ in preclinical models and clinical studies of primary HLH
• Clinical data for pediatric patients with primary HLH

Click Here To Pre-Register

This non-CME symposium is supported by Sobi, Inc.

This non-CE symposium will feature a panel discussion with ITP experts on the use of a recently-approved TPO-receptor agonist for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP). Panelists will discuss two pediatric case studies that dive deeper into the pediatric clinical trials and efficacy of the treatment.

This non-CME symposium is supported by Amgen, Inc.

The types of genomic alterations and oncogenic drivers across pediatric malignancies differ from adult malignancies. Existing genomic profiling tools developed for adult cancers are not optimized for childhood and adolescent cancers. Pediatric cancer patients also have to go through various drug regimens during the course of their therapy.

Join us for a symposium during ASPHO 2019 where we will explore a next-generation sequencing (NGS) assay specifically designed to detect relevant markers across the spectrum of pediatric malignancies. We will also discuss pre-emptive pharmacogenomics at pediatric cancer centers that may in the future assist in drug decision making.

This non-CME symposium is supported by Thermo Fisher Scientific. 

This non-CME symposium. A panel discussion covering clinical trial data, novel mechanism of action, dosing and administration, prescribing information, and important safety information. Unique perspective from a caregiver will be shared.

This non-CME symposium is supported by Genentech.

Click Here To Register

Learn more about identifying and treating TRK fusion cancer.

This non-CME symposium is supported by Bayer.

Speakers:

• Dr. Caterina P. Minniti, Director, Sickle Cell Center Montefiore Medical Center – Covering the “Understanding the pathophysiologic processes involved in anemia and hemolysis-related end-organ damage in SCD”
• Dr. Winfred Wang, St Jude Children’s Research Hospital – Covering “Discuss the impact of anemia and hemolysis on brain health in pediatric patients with SCD, and the importance of screening, including neurocognitive testing and MRI imaging”
• Dr. Robert Clark Brown, Director of Sickle Cell Program at Scottish Rite – Covering “Evaluate existing treatments and emerging drug therapies for treating chronic anemia in SCD.”

Sickle cell disease (SCD) is a debilitating hemoglobinopathy characterized by anemia, hemolysis and vaso-occlusion. Scientific literature suggests an association between anemia, hemolysis and end-organ damage. This symposium will discuss clinical manifestations of hemolytic anemia related to organ damage, highlight the importance of brain health and review emerging therapies targeting anemia and hemolysis.

Educational Objectives

• Understanding pathophysiologic processes involved in anemia and hemolysis-related end-organ damage in SCD
• Discuss the impact of anemia and hemolysis on brain health in pediatric patients with SCD, and the importance of screening, including neurocognitive testing and MRI imaging
• Evaluate existing treatments and emerging drug therapies for treating chronic anemia in SCD.

This non-CME symposium is supported by Global Blood Therapeutics.

Presented by: Dr. Julie Kantor, MD, Associate Professor Department of Hematology/Oncology at University of Alabama Birmingham

This Educational Theater presentation is sponsored by Terumo BCT.

Join us for a discussion on primary hemophagocytic lymphohistiocytosis (HLH) and the first and only FDA approved treatment designed specifically to target interferon gamma in this rare and life-threatening disease.

This Educational Theater presentation is sponsored by Sobi.